Synthesis And Evaluation Of A Novel Series Of 2,7-Substituted-6-Tetrazolyl-1,2,3,4-Tetrahydroisoquinoline Derivatives As Selective Peroxisome Proliferator-Activated Receptor Gamma Partial Agonists

A novel series of 7-substituted-2-[3-(2-furyl)acryloyl]-6-tetrazolyl-1,2,3,4-tetrahydroisoquinoline derivatives were synthesized to clarify structure-activity relationships for peroxisome proliferator-activated receptor gamma (PPAR gamma) partial agonist activity and identify more efficacious PPAR gamma partial agonists with minor adverse effects. Among the derivatives synthesized, compound 26v with a 2-(2,5-dihydropyrrol-1-yl)-5-methyloxazol-4-ylmethoxy group at the 7-position of the tetrahydroisoquinoline structure exhibited stronger PPAR gamma agonist and antagonist activities (EC50 = 6 nM and IC50 = 101 nM) than previously reported values for compound 1 (EC50 = 13 nM and IC50 = 512 nM). Compound 26v had very weak protein tyrosine phosphatase 1B (PTP1B) inhibitory activity and showed higher oral absorption (C-max = 11.4 mu g/mL and area under the curve (AUC) = 134.7 mu g.h/mL) than compound 1 (C-max = 7.0 mu g/mL and AUC = 63.9 mu g.h/mL) in male Sprague-Dawley (SD) rats. A computational docking calculation revealed that 26v bound to PPAR gamma in a similar manner to that of compound 1. In male Zucker fatty rats, 26v and pioglitazone at 10 and 30 mg/kg for 4 weeks similarly reduced plasma triglyceride levels, increased plasma adiponectin levels, and attenuated increases in plasma glucose levels in the oral glucose tolerance test, while only pioglitazone decreased hematocrit values. In conclusion, 6-tetrazolyl-1,2,3,4-tetrahydroisoquinoline derivatives provide a novel scaffold for selective PPAR gamma partial agonists and 26v attenuates insulin resistance possibly by adiponectin enhancements with minor adverse effects.